186 related articles for article (PubMed ID: 25784271)
1. [Therapy of low-grade nonmuscle-invasive bladder cancer].
Olbert PJ; Ohlmann CH; Schwentner C
Urologe A; 2015 Apr; 54(4):484-90. PubMed ID: 25784271
[TBL] [Abstract][Full Text] [Related]
2. [Non-muscle-invasive high-grade bladder cancer].
Gakis G; Stenzl A; Horn T; Gschwend JE; Otto W; Burger M
Urologe A; 2015 Apr; 54(4):491-8. PubMed ID: 25802103
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostics of nonmuscle-invasive urothelial cell carcinoma of the bladder].
Tschirdewahn S; Vom Dorp F
Urologe A; 2015 Apr; 54(4):480-3. PubMed ID: 25784270
[TBL] [Abstract][Full Text] [Related]
4. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
5. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
6. [Non-invasive urinary diagnosis of bladder cancer. What do we know?].
Kausch I; Böhle A
Urologe A; 2003 Jul; 42(7):912-21. PubMed ID: 12898034
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
Kausch von Schmeling I
Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
9. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
10. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
11. [Urine cytology and urine markers. Significance for clinical practice].
Tritschler S; Zaak D; Knuechel R; Stief CG
Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
[TBL] [Abstract][Full Text] [Related]
12. Prediction of muscle invasion of bladder cancer by cystoscopy.
Satoh E; Miyao N; Tachiki H; Fujisawa Y
Eur Urol; 2002 Feb; 41(2):178-81. PubMed ID: 12074406
[TBL] [Abstract][Full Text] [Related]
13. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
[TBL] [Abstract][Full Text] [Related]
14. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
[TBL] [Abstract][Full Text] [Related]
15. [Superficial bladder cancer: Transurethral resection and instillation therapy].
Schenck M; Lümmen G
Urologe A; 2015 Apr; 54(4):499-503. PubMed ID: 25794589
[TBL] [Abstract][Full Text] [Related]
16. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
17. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
[TBL] [Abstract][Full Text] [Related]
18. [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update].
Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
Actas Urol Esp; 2012; 36(7):389-402. PubMed ID: 22386115
[TBL] [Abstract][Full Text] [Related]
19. The management of superficial bladder cancer.
Dalbagni G
Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
[TBL] [Abstract][Full Text] [Related]
20. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]